The'purpose of the Histopathology Facility (HF) is to facilitate research conducted by funded investigators at Fox Chase Cancer Center (FCCC) by providing histology and pathology services including processing of cells and tissues as well as helping in the interpretation of results. The Facility's Technicians and Pathologist play a major support role in numerous research projects at the Center and their contributions have been, and continue to be of great significance in the establishment and characterization of animal models of human cancer. The Facility prepares, processes, and assists in evaluating tissues derived from experimental protocols developed by peer-reviewed, funded investigators. Most of the projects involve animal models of human cancer that require complex histological and/or cytological processing to determine morphological alterations, as well as to localize cancer-relevant gene products. The most frequently utilized services of the Facility during 2005-2009 include: laboratory animal autopsy, fixation, embedding and sectioning of paraffin-embedded tissue blocks (8,000-12,000 per year), unstained paraffin sections for immunohistochemistry (IHC) and laser capture microdissection (LCM) (9,000-14,000 per year), cryomicrotomy (200-1,500 per year), special stains (200-500 per year), immunohistochemistry (IHC) (2,100-3,700 per year), digital microphotography (3,000-5,000 per year), and interpretative histopathology (7,000- 10,000 H&E and IHC slides signed-out per year). During the last CCSG funding cycle we have seen a steady need for all services rendered and significant increase (100%) in the number of frozen sections performed. Furthermore, during 2005-2010 we consolidated new technology such as the web-based Experimental Histopathology database and introduced computerized image analysis. The HF also provides support to the Laboratory Animal Facility (LAF) in quality control and animal health monitoring activities, as well as processing support to the Biosample Repository Facility (BRF) and the LCM component of the Genomics Facility (GF). The HF was used by 39 peer-reviewed, funded investigators in all five Research Programs at FCCC, in calendar year 2009.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Research Institute of Fox Chase Cancer Center
United States
Zip Code
Austin, Steven R; Wong, Yu-Ning; Uzzo, Robert G et al. (2015) Why Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score Work. Med Care 53:e65-72
Bassi, Daniel E; Cenna, Jonathan; Zhang, Jirong et al. (2015) Enhanced aggressiveness of benzopyrene-induced squamous carcinomas in transgenic mice overexpressing the proprotein convertase PACE4 (PCSK6). Mol Carcinog 54:1122-31
Sherman, Kerry A; Miller, Suzanne M; Roussi, Pagona et al. (2015) Factors predicting adherence to risk management behaviors of women at increased risk for developing lymphedema. Support Care Cancer 23:61-9
Eytan, Esther; Wang, Kexi; Miniowitz-Shemtov, Shirly et al. (2014) Disassembly of mitotic checkpoint complexes by the joint action of the AAA-ATPase TRIP13 and p31(comet). Proc Natl Acad Sci U S A 111:12019-24
Johnson, Matthew E; Handorf, Elizabeth A; Martin, Jeffrey M et al. (2014) Postmastectomy radiation therapy for T3N0: a SEER analysis. Cancer 120:3569-74
Gabitova, Linara; Gorin, Andrey; Astsaturov, Igor (2014) Molecular pathways: sterols and receptor signaling in cancer. Clin Cancer Res 20:28-34
Silverman, Diana; Ruth, Karen; Sigurdson, Elin R et al. (2014) Skin involvement and breast cancer: are T4b lesions of all sizes created equal? J Am Coll Surg 219:534-44
Gupta, Sapna; Melnyk, Stepan B; Kruger, Warren D (2014) Cystathionine *-synthase-deficient mice thrive on a low-methionine diet. FASEB J 28:781-90
Simhan, Jay; Smaldone, Marc C; Egleston, Brian L et al. (2014) Nephron-sparing management vs radical nephroureterectomy for low- or moderate-grade, low-stage upper tract urothelial carcinoma. BJU Int 114:216-20
Gowrishankar, Banumathy; Ibragimova, Ilsiya; Zhou, Yan et al. (2014) MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biol Ther 15:329-41

Showing the most recent 10 out of 475 publications